[go: up one dir, main page]

FR23C1004I1 - FCRN ANTAGONISTS AND METHODS OF USE - Google Patents

FCRN ANTAGONISTS AND METHODS OF USE

Info

Publication number
FR23C1004I1
FR23C1004I1 FR23C1004C FR23C1004C FR23C1004I1 FR 23C1004 I1 FR23C1004 I1 FR 23C1004I1 FR 23C1004 C FR23C1004 C FR 23C1004C FR 23C1004 C FR23C1004 C FR 23C1004C FR 23C1004 I1 FR23C1004 I1 FR 23C1004I1
Authority
FR
France
Prior art keywords
methods
fcrn antagonists
fcrn
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1004C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX BVBA
University of Texas System
University of Texas at Austin
Original Assignee
ArgenX BVBA
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52347464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR23C1004(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ArgenX BVBA, University of Texas System, University of Texas at Austin filed Critical ArgenX BVBA
Publication of FR23C1004I1 publication Critical patent/FR23C1004I1/en
Application granted granted Critical
Publication of FR23C1004I2 publication Critical patent/FR23C1004I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
FR23C1004C 2013-12-24 2023-01-12 FCRN ANTAGONISTS AND METHODS OF USE Active FR23C1004I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361920547P 2013-12-24 2013-12-24
PCT/US2014/072087 WO2015100299A1 (en) 2013-12-24 2014-12-23 Fcrn antagonists and methods of use

Publications (2)

Publication Number Publication Date
FR23C1004I1 true FR23C1004I1 (en) 2023-03-10
FR23C1004I2 FR23C1004I2 (en) 2024-01-05

Family

ID=52347464

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1004C Active FR23C1004I2 (en) 2013-12-24 2023-01-12 FCRN ANTAGONISTS AND METHODS OF USE

Country Status (26)

Country Link
US (3) US10316073B2 (en)
EP (2) EP3087095B1 (en)
JP (2) JP6554473B2 (en)
KR (3) KR20240033084A (en)
CN (2) CN112142843B (en)
AU (1) AU2014369999B2 (en)
BR (1) BR112016014810B1 (en)
CA (1) CA2934644C (en)
DK (1) DK3087095T3 (en)
EA (1) EA035324B1 (en)
ES (1) ES2742682T3 (en)
FI (1) FIC20230003I1 (en)
FR (1) FR23C1004I2 (en)
HU (2) HUE046822T2 (en)
IL (1) IL246223B (en)
LT (2) LT3087095T (en)
LU (1) LUC00284I2 (en)
MX (1) MX368804B (en)
NL (1) NL301203I2 (en)
NO (1) NO2022049I1 (en)
NZ (1) NZ722055A (en)
PL (1) PL3087095T3 (en)
PT (1) PT3087095T (en)
SG (2) SG10202009832XA (en)
WO (1) WO2015100299A1 (en)
ZA (1) ZA201604464B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ722055A (en) 2013-12-24 2020-02-28 Univ Texas Fcrn antagonists and methods of use
EP3268391B1 (en) * 2015-03-09 2021-08-11 argenx BVBA Methods of reducing serum levels of fc-containing agents using fcrn antagonsits
FR3038517B1 (en) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY
CN106957364B (en) * 2016-01-11 2021-03-16 上海交通大学 A kind of monoclonal antibody FnAb12 and its application
CN106957365B (en) * 2016-01-11 2021-03-16 上海交通大学 A kind of monoclonal antibody FnAb8 and its application
EP3257866A1 (en) * 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
CA3030099A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
CA3045797A1 (en) * 2016-12-02 2018-06-07 The Texas A&M University System Fusion proteins for selectively depleting antigen-specific antibodies
MA50958A (en) 2017-04-21 2020-10-14 Staten Biotechnology B V ANTI-APOC3 ANTIBODIES AND THEIR METHODS OF USE
JP7039694B2 (en) 2017-10-31 2022-03-22 スターテン・バイオテクノロジー・ベー・フェー Anti-APOC3 antibody and how to use it
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
SG11202003944WA (en) * 2017-12-08 2020-06-29 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
MA52790A (en) * 2018-06-08 2021-04-14 Argenx Bvba COMPOSITIONS AND METHODS OF TREATMENT OF IMMUNE THROMBOPENIA
US20210340251A1 (en) * 2018-07-20 2021-11-04 Momenta Pharmaceuticals, Inc. Fcrn antibody compositions
WO2020054979A1 (en) * 2018-09-12 2020-03-19 아주대학교산학협력단 Composition comprising cd83 inhibitor as effective ingredient for preventing or treating behcet's disease
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
JOP20210298A1 (en) 2019-05-14 2023-01-30 Provention Bio Inc Methods and compositions for preventing type 1 diabetes
MA56102A (en) * 2019-06-07 2022-04-13 Argenx Bvba PHARMACEUTICAL FORMULATIONS OF FCRN INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION
KR20220148804A (en) * 2020-01-08 2022-11-07 아르젠엑스 비브이 Methods of Treatment of Pemphigus Disorder
CN114341184B (en) * 2020-02-10 2023-04-04 北京拓界生物医药科技有限公司 anti-FcRn antibodies, antigen binding fragments thereof, and medical uses thereof
CN113769058B (en) * 2020-06-10 2024-09-06 上海宝济药业股份有限公司 Pharmaceutical composition and application thereof
JP2023530109A (en) 2020-06-11 2023-07-13 プロヴェンション・バイオ・インコーポレイテッド Methods and compositions for preventing type 1 diabetes
EP4359432A2 (en) 2021-06-23 2024-05-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Short apoc-ii mimetic peptides and methods of use
CN118488967A (en) 2022-01-18 2024-08-13 阿根思有限公司 Galectin-10 antibodies
TW202337895A (en) 2022-02-21 2023-10-01 比利時商阿根思公司 Methods for treating myositis using fcrn antagonists
EP4508074A1 (en) 2022-04-13 2025-02-19 Ose Immunotherapeutics New class of molecules for selective clearance of antibody
IL316418A (en) 2022-05-05 2024-12-01 Us Health Short apolipoprotein e mimetic peptides and methods of use
EP4540283A1 (en) 2022-06-15 2025-04-23 argenx BV Fcrn/hsa binding molecules and methods of use
CN115645537A (en) * 2022-10-25 2023-01-31 成都臻拓医药科技有限公司 Application of FcRn inhibitor in preparation of medicine for inhibiting recurrence of autoimmune disease
CN120344557A (en) * 2022-11-14 2025-07-18 阿根思有限公司 FCRN antagonist molecules and methods of use thereof
TW202444412A (en) 2023-02-04 2024-11-16 美商默門塔醫藥公司 Compositions and methods for treating hemolytic disease of the fetus and newborn
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
TW202506723A (en) * 2023-03-24 2025-02-16 美商派拉岡醫療公司 Fc fragments that bind fcrn and methods of use
WO2025008537A1 (en) 2023-07-05 2025-01-09 Ablynx Nv Improved fcrn antagonists for treatment of igg-related diseases and disorders
WO2025017368A1 (en) 2023-07-16 2025-01-23 argenx BV Methods of treating chronic inflammatory demyelinating polyneuropathy
WO2025057086A2 (en) 2023-09-11 2025-03-20 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions of fcrn antibodies
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis
GB202319605D0 (en) 2023-12-20 2024-01-31 argenx BV Monovalent binding molecules and methods of use

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62153300A (en) * 1985-12-26 1987-07-08 Teijin Ltd Fc region protein of human immunoglobulin g and production thereof
DE3883899T3 (en) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. CHANGED ANTIBODIES.
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5326856A (en) 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
JPH08511420A (en) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド Body
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
WO1996022024A1 (en) 1995-01-17 1996-07-25 Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6128119A (en) 1997-01-10 2000-10-03 Asahi Kogaku Kogyo Kabushiki Kaisha Beam shaping optical system
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HU230769B1 (en) 1999-01-15 2018-03-28 Genentech Inc. Polypeptide variants with altred effector function
AU4314801A (en) 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6992234B2 (en) 2000-11-06 2006-01-31 The Jackson Laboratory FcRn-based therapeutics for the treatment of auto-immune disorders
CA2467781C (en) 2000-11-20 2014-09-23 Canadian Blood Services Use of a monoclonal antibody specific for a red blood cell to inhibit the reticuloendothelial system for the treatment of thrombocytopenia
DE60143544D1 (en) 2000-12-12 2011-01-05 Medimmune Llc MOLECULES WITH LONGER MID-TERM, COMPOSITIONS AND THEIR USE
WO2003011878A2 (en) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP3945281B2 (en) 2002-03-19 2007-07-18 富士ゼロックス株式会社 Image forming apparatus
EP1513554B9 (en) 2002-05-30 2011-11-09 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
WO2004016750A2 (en) 2002-08-14 2004-02-26 Macrogenics, Inc. FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
EP1562972B1 (en) 2002-10-15 2010-09-08 Facet Biotech Corporation ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2513025A1 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. Dual expression vector system for antibody expression in bacterial and mammalian cells
EP2052713A3 (en) 2003-01-13 2009-05-20 Macrogenics, Inc. Soluble FcgammaR fusion proteins and methods of use thereof
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
EP1798864A4 (en) 2004-09-30 2013-07-31 Brother Ind Ltd WIRELESS LABEL COMMUNICATION APPARATUS, WIRELESS LABEL, WIRELESS LABEL COMMUNICATION SYSTEM, AND WIRELESS COMMUNICATION METHOD
US20100266530A1 (en) * 2005-04-29 2010-10-21 The Jackson Laboratory FcRN ANTIBODIES AND USES THEREOF
US8163881B2 (en) * 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
AU2008254951A1 (en) 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain Fc (ScFc) regions, binding polypeptides comprising same, and methods related thereto
MX394440B (en) * 2007-06-01 2025-03-24 Univ Maryland IMMUNOGLOBULIN FC CONSTANT REGION RECEPTOR BINDING AGENTS.
US8195661B2 (en) 2007-11-27 2012-06-05 Umber Systems Method and apparatus for storing data on application-level activity and other user information to enable real-time multi-dimensional reporting about user of a mobile data network
US9260525B2 (en) * 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
US20110059091A1 (en) * 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
WO2009131702A2 (en) 2008-04-25 2009-10-29 Dyax Corp. Antibodies against fcrn and use thereof
WO2010014909A1 (en) * 2008-08-01 2010-02-04 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
NO2486141T3 (en) 2009-10-07 2018-06-09
JP5826270B2 (en) * 2010-07-28 2015-12-02 グリックニック インコーポレイテッド Fusion proteins of natural human protein fragments for making regularly multimerized immunoglobulin Fc compositions
GB201111291D0 (en) 2011-06-30 2011-08-17 Agco Int Gmbh Engine control system
EP2771694A4 (en) 2011-10-26 2015-08-05 Novartis Tiergesundheit Ag MONOCLONAL ANTIBODIES AND METHODS OF USE
US20140302028A1 (en) 2011-11-18 2014-10-09 Merck Sharp & Dohme Corp. Fc containing polypeptides having increased anti-inflammatory properties and increased fcrn binding
KR102041412B1 (en) * 2011-12-30 2019-11-11 한미사이언스 주식회사 Derivatives of Immunglobulin Fc fragment
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
CN119020380A (en) 2012-07-05 2024-11-26 弗·哈夫曼-拉罗切有限公司 Expression and secretion system
GB201302878D0 (en) 2013-02-19 2013-04-03 Argen X Bv Modified igG molecules
KR101815265B1 (en) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn specific human antibody and composition for treatment of autoimmune diseases
CA2966352A1 (en) 2013-11-26 2015-06-04 The Brigham And Women's Hospital, Inc. Compositions and methods for modulating an immune response
NZ722055A (en) 2013-12-24 2020-02-28 Univ Texas Fcrn antagonists and methods of use
LT3193930T (en) 2014-09-17 2019-10-25 Affibody Ab New polypeptides
CN118667010A (en) 2015-01-30 2024-09-20 动量制药公司 FcRN antibodies and methods of use thereof
EP3268391B1 (en) 2015-03-09 2021-08-11 argenx BVBA Methods of reducing serum levels of fc-containing agents using fcrn antagonsits
HK1251483A1 (en) 2015-05-12 2019-02-01 Synt免疫公司 Humanized affinity matured anti-fcrn antibodies
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
WO2017012959A1 (en) 2015-07-17 2017-01-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for inducing immune tolerance by mucosal vaccination with fc-coupled antigens
CN106957365B (en) 2016-01-11 2021-03-16 上海交通大学 A kind of monoclonal antibody FnAb8 and its application
GB201618424D0 (en) 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
SG11202003944WA (en) 2017-12-08 2020-06-29 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
MA52790A (en) 2018-06-08 2021-04-14 Argenx Bvba COMPOSITIONS AND METHODS OF TREATMENT OF IMMUNE THROMBOPENIA
EP3969125A4 (en) 2019-05-17 2023-01-11 Alexion Pharmaceuticals, Inc. Use of anti-fcrn antibodies in the treatment of pemphighus and pemphigoid diseases
MA56102A (en) * 2019-06-07 2022-04-13 Argenx Bvba PHARMACEUTICAL FORMULATIONS OF FCRN INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION

Also Published As

Publication number Publication date
SG11201605203UA (en) 2016-07-28
EA035324B1 (en) 2020-05-28
BR112016014810B1 (en) 2023-12-26
BR112016014810A2 (en) 2017-09-19
NL301203I2 (en) 2023-05-24
FR23C1004I2 (en) 2024-01-05
IL246223B (en) 2021-06-30
MX368804B (en) 2019-10-17
WO2015100299A1 (en) 2015-07-02
ES2742682T3 (en) 2020-02-17
CA2934644A1 (en) 2015-07-02
EA201691304A1 (en) 2016-10-31
CN106103476B (en) 2020-11-27
NO2022049I1 (en) 2022-11-23
US10316073B2 (en) 2019-06-11
KR20220152546A (en) 2022-11-16
EP3626738A1 (en) 2020-03-25
JP2019076103A (en) 2019-05-23
JP2017501725A (en) 2017-01-19
KR20160111937A (en) 2016-09-27
US20220275035A1 (en) 2022-09-01
IL246223A0 (en) 2016-07-31
DK3087095T3 (en) 2019-10-28
ZA201604464B (en) 2025-05-28
AU2014369999A1 (en) 2016-07-07
US11505585B2 (en) 2022-11-22
PT3087095T (en) 2019-10-09
LT3087095T (en) 2019-09-10
CN112142843B (en) 2024-10-18
JP6554473B2 (en) 2019-07-31
KR102452173B1 (en) 2022-10-17
CN106103476A (en) 2016-11-09
SG10202009832XA (en) 2020-11-27
HUE046822T2 (en) 2020-03-30
LTPA2022014I1 (en) 2022-12-12
NZ722055A (en) 2020-02-28
US20180179258A1 (en) 2018-06-28
HUS2200048I1 (en) 2022-12-28
CA2934644C (en) 2023-11-21
MX2016008399A (en) 2016-12-15
EP3087095A1 (en) 2016-11-02
PL3087095T3 (en) 2020-03-31
NL301203I1 (en) 2022-11-09
US20150218239A1 (en) 2015-08-06
AU2014369999B2 (en) 2019-12-12
CN112142843A (en) 2020-12-29
EP3087095B1 (en) 2019-08-07
KR20240033084A (en) 2024-03-12
FIC20230003I1 (en) 2023-01-19
LUC00284I2 (en) 2025-05-12

Similar Documents

Publication Publication Date Title
FR23C1004I2 (en) FCRN ANTAGONISTS AND METHODS OF USE
EP2971000A4 (en) PHI-4 POLYPEPTIDES AND METHODS OF USE
EP2986623A4 (en) C3,3-DISUBSTITUTED 19-NOR-C21-N-PYRAZOLYL-STEROIDS AND METHODS OF USE THEREOF
EP3394065A4 (en) TETRAHYDROPYRANYL-AMINO-PYRROLOPYRIMIDINONE AND METHODS OF USE THEREFOR
EP3303435A4 (en) HYDROFLUOROLEFINS AND METHODS OF USE THEREFOR
MA40921A (en) ANTI-GENETIC CHEMERICAL ANTI-CLDN RECEPTORS AND METHODS OF USE
MA51552A (en) ANTI-OX40 ANTIBODIES AND METHODS OF USE
EP3436030A4 (en) CHIMERIC RECEPTORS AND METHODS OF USE
PL3353210T3 (en) Anti-TIGIT antibodies and methods of use
EP2912178A4 (en) SUPER-ACTIVATORS AND METHODS OF USE THEREOF
EP2973789A4 (en) PROTECTED ELECTRODE STRUCTURES AND METHODS
MA42979A (en) ANTI-AGING ANTIBODIES AND RELATED METHODS OF USE
EP2964235A4 (en) ANTIMICROBIAL-ANTIBIOFILM COMPOSITIONS AND METHODS OF USE
IL235401A0 (en) st2l antagonists and methods of use
EP2968369A4 (en) NEUROACTIVE STEROIDS AND METHODS OF USE
EP2961831A4 (en) COMPOSITIONS AND METHODS OF IMMUNOTHERAPY
EP2967683A4 (en) ADAPTABLE INTERVERTEBRAL IMPLANT AND METHODS OF USE
HRP20170840T1 (en) XANTINS SUBSTITUTED AND THEIR METHODS OF USE
EP2951210A4 (en) SELECTIVE DISTRIBUTION OF MOLECULES AND METHODS OF USE
EP2969030A4 (en) LIGHTENING TOPICAL COMPOSITION AND METHODS OF USE
DK2994488T3 (en) USE OF C5AR ANTAGONISTS
EP2967397A4 (en) ELECTRO-SURGICAL ASSOCIATION OF TOOLS AND PROCESSES
EP2948559A4 (en) KV1.3 ANTAGONISTS AND METHODS OF USE
MA45573A (en) ANTI-CD154 ANTIBODIES AND CORRESPONDING METHODS OF USE
EP2994150A4 (en) PROBIOTICS AND METHODS OF USE